Hypoglycaemia occurs often in diabetic patients treated with insulin but relatively infrequently in those taking a sulphonylurea drugs. This risk of hypoglycaemia is the most important single factor limiting the attainment of the therapeutic goal, namely near normal glycaemia. However, in certain types of patient (e.g. patients with a long duration of type 1 diabetes), warning symptoms are not always perceived by the patients even when awake so that appropriate action is not taken and neuroglycopenia then unconsciousness ensue.
Impact Factor
2022: 6.012
This work is licensed under a